Jun 15, 2026Withdrawn0001213900-26-068596
All companies
Trade Regentis Biomaterials Ltd424B3Dec 4, 2025
Regentis Biomaterials Prices Initial Public Offering Regentis Biomaterials prices IPO at $8 per share, raising $10M Regentis Biomaterials Prices $10,000,000 NYSE American IPO Regentis Biomaterials Announces Pricing of $10M IPO
RE
Regentis Biomaterials Ltd
RGNTPublic
PublicUnited States(NYSE)Best valuation $21.39M1 market
Public listing
Listed· NYSE· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NYSEIPO
RGNTPrice
$4.13
24h
-3.73%
Valuation
$21.39M
24h volume
$4.22M
Type
IPO
Trade Regentis Biomaterials LtdNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 2h ago
Regentis Biomaterials Ltd IPO public float & lock-up
Public float and locked shares extracted from Regentis Biomaterials Ltd's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
5.18M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001912966.
Revenue
—
Net income
-$13.65M
Gross margin
—
Cash
$7.38M
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$6.97M | $932K | -$1.93M | — |
| Net income | -$13.65M | $4.8M | -$4.13M | — |
| Cash & equivalents | $7.38M | — | — | — |
| Total assets | $7.62M | $482K | — | — |
| Total liabilities | $2.87M | $6.49M | — | — |
| Shareholders' equity | $4.74M | -$41.1M | -$45.91M | -$42.06M |
About Regentis Biomaterials Ltd
Regentis Biomaterials Ltd is a healthcare and life-sciences company with a business profile centered on medical products, therapies, diagnostics, or health-related services.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Regentis Biomaterials Ltd belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
WithdrawnEDGAR filings resolved from RGNT / CIK 0001912966.
Jun 9, 2026Amended0001213900-26-066555
May 29, 2026Free writing prospectus0001213900-26-062753
May 1, 2026Filed0001213900-26-051034
Jan 7, 2026Confidential draft0001213900-26-002202
424B3PROSPECTUS
Dec 4, 2025Final prospectus0001213900-25-118362
Dec 3, 2025Exchange registration0001143313-25-000093
Oct 24, 2025Free writing prospectus0001213900-25-101902
Oct 24, 2025Amended0001213900-25-101900
Oct 6, 2025Free writing prospectus0001213900-25-096296
Sep 30, 2025Amended0001213900-25-093302
Sep 9, 2025Exchange registration0001213900-25-086109
Latest Regentis Biomaterials Ltd IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
ORTHOWORLDIPO filing
Article states Regentis Biomaterials priced its IPO (ordinary shares at $8.00) and describes the offering terms.
Investing.comIPO filing
IPO pricing coverage for Regentis Biomaterials, including price and proceeds.
StocktitanIPO filing
Stocktitan post on IPO pricing (shares offered, IPO price, proceeds) for Regentis Biomaterials.
AinvestIPO filing
IPO pricing announcement summary for Regentis Biomaterials (pricing and intended use of proceeds).
Regentis Biomaterials Ltd IPO — frequently asked questions
- When did Regentis Biomaterials Ltd go public?
- Regentis Biomaterials Ltd has already gone public and now trades publicly on NYSE under the ticker RGNT.
- Can I buy Regentis Biomaterials Ltd stock?
- Yes — Regentis Biomaterials Ltd is publicly traded on NYSE as RGNT. You can follow its live price, valuation and post-IPO performance above.
- What is Regentis Biomaterials Ltd's valuation?
- Regentis Biomaterials Ltd's most recent valuation tracked here is $21.39M, derived from live market prices.